Drugs / anti-CD20/CD30-CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06519344 | Jul 2024 → Jul 2026 overdue | B-cell neoplasm | Shanghai Tongji Hospital, Tongji University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD20/CD30-CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06519344 ↗ |
| Modality | Cell therapy | “anti-CD20/CD30-CAR-T cell therapy” NCT06519344 ↗ |
| Route | Intravenous | “anti-CD20/CD30-CAR-T cells are administered intravenously via an infusion pump” NCT06519344 ↗ |